The Effects of Bromelain Supplement in Patients With Ulcerative Colitis
NCT ID: NCT06351696
Last Updated: 2024-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
84 participants
INTERVENTIONAL
2024-04-20
2024-08-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Broccoli Sprouts for Mild Ulcerative Colitis
NCT05507931
Dietary Treatment of Crohn's Disease
NCT00343642
Effects of Pomegranate Juice on Ulcerative Colitis
NCT07115862
Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases
NCT02179372
Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer
NCT02069561
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Bromleine
Bromlein
1500 mg/day
Placebo
Placebo
Placebo
Placebo (1500 mg/day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bromlein
1500 mg/day
Placebo
Placebo (1500 mg/day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no other chronic disorders
Exclusion Criteria
* those who have relapses that required hospitalization and change the type and dosage of medications during the intervention
* patients who do not want to continue the study protocol
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Nutrition and Food Technology Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Azita Hekmatdoost
Principle Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Azita Hekmatdoost, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Shahid Beheshti University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azita Hekmatdoost
Tehran, Middle East, Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
43008563
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.